U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07654400) titled 'A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer' on June 12.
Brief Summary: This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Extensive-stage Small-cell Lung Cancer
Intervention:
DRUG: BL-M14D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUG: Atezolizumab
Administration by intravenous infusion for a cycle of 3 weeks.
Recruitment Status: NOT_YET_RECRUITIN...